Abstract
Objectives: This retrospective analysis aims at describing the safety profile of treatment with pegylated liposomal doxorubicin (PLD) and oxaliplatin in recurrent ovarian cancer patients who experienced myelotoxicity (principally neutropenia) during first line chemotherapy with carboplatin and paclitaxel. Methods: We reviewed the medical records of patients with relapsed ovarian cancer treated with PLD/Oxaliplatin at the Istituto Oncologico Veneto (IOV)/IRCCS, Padua University between 2002 and 2008. Results: A cohort of 16 patients who developed myelodepression and other toxicities of grade 3 to grade 4 during first line chemotherapy with carboplatin/paclitaxel, were selected for this retrospective study. Patients had developed predominantly grade 3 to grade 4 neutropenia and grade 1 to grade 3 thrombocytopenia as major toxicities during primary chemotherapy with carboplatin and paclitaxel. Following relapse or disease progression, PLD/oxaliplatin chemotherapy was administered at 30 to 35 and 70 mg/m, respectively, over 2 day, every 4 weeks. Conclusions: Complete regression and stabilization of bone marrow suppression and no allergic reactions were seen with PLD/oxaliplatin treatment. The estimated median overall survival was 51.2 months. PLD/oxaliplatin chemotherapy did not show hematological toxicity and was feasible and active in this group of pretreated frail patients.
| Original language | English |
|---|---|
| Pages (from-to) | 305-308 |
| Number of pages | 4 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 34 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 2011 |
Fingerprint
Keywords
- carboplatin
- myelotoxicity
- ovarian cancer
- oxaliplatin
- paclitaxel
- pegylated liposomal doxorubicin
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment. / Palma, Maurizia Dalla; Lombardi, Giuseppe; Donach, Martin E.; Borgato, Lucia; Zustovich, Fable; Furini, Lara; Nicoletto, Maria O.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 34, No. 3, 06.2011, p. 305-308.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment
AU - Palma, Maurizia Dalla
AU - Lombardi, Giuseppe
AU - Donach, Martin E.
AU - Borgato, Lucia
AU - Zustovich, Fable
AU - Furini, Lara
AU - Nicoletto, Maria O.
PY - 2011/6
Y1 - 2011/6
N2 - Objectives: This retrospective analysis aims at describing the safety profile of treatment with pegylated liposomal doxorubicin (PLD) and oxaliplatin in recurrent ovarian cancer patients who experienced myelotoxicity (principally neutropenia) during first line chemotherapy with carboplatin and paclitaxel. Methods: We reviewed the medical records of patients with relapsed ovarian cancer treated with PLD/Oxaliplatin at the Istituto Oncologico Veneto (IOV)/IRCCS, Padua University between 2002 and 2008. Results: A cohort of 16 patients who developed myelodepression and other toxicities of grade 3 to grade 4 during first line chemotherapy with carboplatin/paclitaxel, were selected for this retrospective study. Patients had developed predominantly grade 3 to grade 4 neutropenia and grade 1 to grade 3 thrombocytopenia as major toxicities during primary chemotherapy with carboplatin and paclitaxel. Following relapse or disease progression, PLD/oxaliplatin chemotherapy was administered at 30 to 35 and 70 mg/m, respectively, over 2 day, every 4 weeks. Conclusions: Complete regression and stabilization of bone marrow suppression and no allergic reactions were seen with PLD/oxaliplatin treatment. The estimated median overall survival was 51.2 months. PLD/oxaliplatin chemotherapy did not show hematological toxicity and was feasible and active in this group of pretreated frail patients.
AB - Objectives: This retrospective analysis aims at describing the safety profile of treatment with pegylated liposomal doxorubicin (PLD) and oxaliplatin in recurrent ovarian cancer patients who experienced myelotoxicity (principally neutropenia) during first line chemotherapy with carboplatin and paclitaxel. Methods: We reviewed the medical records of patients with relapsed ovarian cancer treated with PLD/Oxaliplatin at the Istituto Oncologico Veneto (IOV)/IRCCS, Padua University between 2002 and 2008. Results: A cohort of 16 patients who developed myelodepression and other toxicities of grade 3 to grade 4 during first line chemotherapy with carboplatin/paclitaxel, were selected for this retrospective study. Patients had developed predominantly grade 3 to grade 4 neutropenia and grade 1 to grade 3 thrombocytopenia as major toxicities during primary chemotherapy with carboplatin and paclitaxel. Following relapse or disease progression, PLD/oxaliplatin chemotherapy was administered at 30 to 35 and 70 mg/m, respectively, over 2 day, every 4 weeks. Conclusions: Complete regression and stabilization of bone marrow suppression and no allergic reactions were seen with PLD/oxaliplatin treatment. The estimated median overall survival was 51.2 months. PLD/oxaliplatin chemotherapy did not show hematological toxicity and was feasible and active in this group of pretreated frail patients.
KW - carboplatin
KW - myelotoxicity
KW - ovarian cancer
KW - oxaliplatin
KW - paclitaxel
KW - pegylated liposomal doxorubicin
UR - http://www.scopus.com/inward/record.url?scp=79958292487&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958292487&partnerID=8YFLogxK
U2 - 10.1097/COC.0b013e3181e1cb22
DO - 10.1097/COC.0b013e3181e1cb22
M3 - Article
VL - 34
SP - 305
EP - 308
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 3
ER -